ASCO 2017 | The future of inhibiting Bcl2 for the treatment of T-ALL

Kim Kampen • 22 Jun 2017

T-Cell Lymphoma Venetoclax

Kim Kampen, PhD, University of Leuven, Leuven, Belgium, talks to us about conducting clinical trials for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) cases, specifically by targeting Bcl2, a pro-survival protein. Dr. Kampen explains that it is necessary to expand the patient population for trials by including other ALL conditions that are known to be responsive to Bcl2 inhibition, for example, early T-cell precursor ALL (ETP T-ALL), which is responsive to venetoclax. She hopes that these trials will produce data supporting Bcl2 inhibition in treating T-ALL, which would allow the reduction of chemotherapy to reduce toxicity levels of patients in the long-term run. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.